Guangdong Association Of Clinical Trials

This phase 2 trial tests whether combining chidamide (a pill) with ivonescimab (an infusion) can help people with advanced non-small cell lung cancer whose tumors have stopped responding to immunotherapy and have a specific protein marker called YAP. The study will enroll 32 adul…

This study looks at how well the immunotherapy drug ivonescimab works when used alone as the first treatment for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive) and no targetable gene mutations. About 265 participants will receive ivone…

This early study will test a personalized mRNA vaccine (RGL-270) given together with standard immunotherapy drugs in 40 people with advanced non-small cell lung cancer. The vaccine is custom-made to target unique markers on each person's tumor. The main goal is to check safety an…

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer still shows signs of activity (detected by a blood test) after taking the drug osimertinib alone. The trial will test whether adding a second drug, sacituzumab tirumotecan, can improve out…

This study tests a combination of two drugs (IBI351 and cetuximab β) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 48 participants will receive the treatment to see if it shrinks tumors and how safe it is. The goal i…

This study is for people with stage II-IIIB non-small cell lung cancer whose tumors did not fully disappear after initial chemotherapy plus immunotherapy. Researchers will use a blood test to look for tiny bits of cancer DNA (called MRD) to decide if additional immunotherapy with…

Researchers are studying whether a blood test that looks for tiny traces of cancer DNA can identify early-stage lung cancer patients who are unlikely to need extra treatment after surgery. The trial enrolls adults with stage IB to IIIA non-small cell lung cancer who have had comp…